They also should analyze the beneficial effects of cardiovascular drugs such as statins and ACE inhibitors on these surrogate markers (indicators of arterial stiffness, endothelial function and cognitive performance) in NAFLD subjects. The gene discussed is ACE; the disease is metabolic dysfunction-associated steatotic liver disease.